Sector News

Seattle Genetics on a ‘great trajectory,’ looks to grow staff by 100

April 24, 2015
Life sciences
Seattle Genetics is hiring for 100 positions, Chief Operating Officer Eric Dobmeier said Thursday.
 
The Bothell-based biotech company (Nasdaq: SGEN) is looking to fill positions ranging from biostatisticians and research associates to the head of its cancer research program and vice president of marketing.
 
That growth is to keep the company, which develops cancer treatments, on track with what a Seattle Genetics spokeswoman called a “great trajectory.”
 
Hiring new people will also coincide with the company ramping up spending in coming years to support preclinical developments, clinical trial activities and continue the commercialization of its flagship product Adcetris, according to a recent filing with the Securities and Exchange Commission. Adcetris is used to treat lymphoma.
 
Seattle Genetics is also investing heavily in its pipeline. That was one factor that led to a $27 million loss in the fourth quarter last year.
 
Even after that loss, though, the company’s stock held steady. Today it is trading at about $37 per share.
 
The company will report first quarter earnings next week.
 
By Annie Zak
 

comments closed

Related News

June 22, 2024

Ferring launches online assessment tool, educational platform around male fertility

Life sciences

Because infertility is often branded largely as a women’s issue, many men may be unaware of their own possible role in the matter and may not undergo testing in a timely manner—even though research has shown that men “substantially” contribute to about half of all cases of infertility.

June 22, 2024

Johnson & Johnson blueprints €125M plant upgrade as part of 5-year Italy investment

Life sciences

After plugging nearly 50 million euros into its Italy R&D in the first half of the decade, Johnson & Johnson Innovative Medicine is significantly upping its commitment to the country. Over the next five years, J&J Innovative Medicine, which recently rebranded from Janssen, will plug a projected 580 million euros ($621.7 million) into its Italian business, the company said in a press release.

June 22, 2024

India’s Lupin announces CEO pick for new subsidiary as it moves into the CDMO arena

Life sciences

From vitamin maker to pharmaceutical specialist and now contract manufacturer, India’s Lupin is embarking on a new phase of its corporate journey. Lupin on Monday unveiled its new subsidiary, Lupin Manufacturing Solutions, which is poised to work on the development, production and sale of active pharmaceutical ingredients.

How can we help you?

We're easy to reach